SG10202103003RA - Polymer protein microparticles - Google Patents
Polymer protein microparticlesInfo
- Publication number
- SG10202103003RA SG10202103003RA SG10202103003RA SG10202103003RA SG10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA SG 10202103003R A SG10202103003R A SG 10202103003RA
- Authority
- SG
- Singapore
- Prior art keywords
- polymer protein
- protein microparticles
- microparticles
- polymer
- protein
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161561525P | 2011-11-18 | 2011-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202103003RA true SG10202103003RA (en) | 2021-05-28 |
Family
ID=47295198
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202103003RA SG10202103003RA (en) | 2011-11-18 | 2012-11-18 | Polymer protein microparticles |
SG11201402152YA SG11201402152YA (en) | 2011-11-18 | 2012-11-18 | Polymer protein microparticles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201402152YA SG11201402152YA (en) | 2011-11-18 | 2012-11-18 | Polymer protein microparticles |
Country Status (20)
Country | Link |
---|---|
US (4) | US20130129830A1 (fr) |
EP (4) | EP2790681B9 (fr) |
JP (5) | JP6267649B2 (fr) |
KR (4) | KR102133352B1 (fr) |
CN (2) | CN103957898B (fr) |
AU (1) | AU2012340107B2 (fr) |
BR (1) | BR112014011915B1 (fr) |
CA (2) | CA3076725A1 (fr) |
DK (3) | DK2790681T4 (fr) |
ES (3) | ES2810003T3 (fr) |
FI (1) | FI2790681T4 (fr) |
HU (2) | HUE051644T2 (fr) |
IL (4) | IL303832A (fr) |
MX (2) | MX362286B (fr) |
PL (3) | PL3574897T3 (fr) |
PT (2) | PT3574897T (fr) |
RU (2) | RU2768492C2 (fr) |
SG (2) | SG10202103003RA (fr) |
WO (1) | WO2013075068A1 (fr) |
ZA (3) | ZA201403379B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (fr) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
SG10202103003RA (en) | 2011-11-18 | 2021-05-28 | Regeneron Pharma | Polymer protein microparticles |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US20140010861A1 (en) | 2012-04-02 | 2014-01-09 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
JP2016530294A (ja) | 2013-09-03 | 2016-09-29 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | キメラポリヌクレオチド |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CA2955250A1 (fr) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Polynucleotides chimeriques |
PL3389636T3 (pl) * | 2015-12-16 | 2022-11-28 | Regeneron Pharmaceuticals, Inc. | Kompozycje i metody wytwarzania mikrocząstek białkowych |
HRP20220525T1 (hr) | 2015-12-23 | 2022-05-27 | Modernatx, Inc. | Postupci uporabe polinukleotida koji kodiraju ligand ox40 |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
EP3400023A1 (fr) | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
EP3625246A1 (fr) | 2017-05-18 | 2020-03-25 | ModernaTX, Inc. | Polynucléotides codant pour des polypeptides d'interleukine-12 (il12) ancrés et leurs utilisations |
EP3459529A1 (fr) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Préparation de formes posologiques solides à libération prolongée comprenant des anticorps par séchage par pulvérisation |
CA3127228A1 (fr) * | 2019-01-30 | 2020-08-06 | Amgen Inc. | Attributs de l'aflibercept et leurs procedes de caracterisation et de modification |
EP4041312A4 (fr) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Procédés de traitement d'un trouble oculaire |
IL293112A (en) * | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
CN115887760A (zh) * | 2022-11-21 | 2023-04-04 | 娜罗曼苏(杭州)医疗生物科技有限公司 | 一种注射用左旋聚乳酸制备工艺 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210529A (en) | 1974-12-26 | 1980-07-01 | Midwest Research Institute | Blood compatible polymers and applications thereof |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4764364A (en) | 1986-02-25 | 1988-08-16 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
US5104221A (en) | 1989-03-03 | 1992-04-14 | Coulter Electronics Of New England, Inc. | Particle size analysis utilizing polarization intensity differential scattering |
DK0417563T3 (da) | 1989-09-12 | 2000-11-06 | Hoffmann La Roche | TNF-bindende proteiner |
GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
AU5018693A (en) | 1992-09-21 | 1994-04-12 | Upjohn Company, The | Sustained-release protein formulations |
GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
AU3729295A (en) | 1994-09-23 | 1996-04-09 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
EP0913177A1 (fr) | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Procédé pour produire des produits amorphe, sec comprenant de la matière biologique active par séchage convectif, spécialement söchage par pulvérisation |
ES2217738T3 (es) | 1998-01-29 | 2004-11-01 | Poly-Med Inc. | Microparticulas absorbibles. |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
AU1226901A (en) | 1999-10-22 | 2001-05-08 | Amgen, Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
FR2809309B1 (fr) * | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
TWI283182B (en) | 2000-08-07 | 2007-07-01 | Nektar Therapeutics | Inhalable spray dried 4-helix bundle protein powders having minimized aggregation |
AU2002322295C1 (en) | 2001-06-21 | 2008-12-18 | Altus Pharmaceuticals Inc. | Spherical protein particles and methods of making and using them |
CN1310671C (zh) * | 2001-07-09 | 2007-04-18 | 安斯泰来制药有限公司 | 缓释注射剂用组合物的制造方法 |
TW574597B (en) | 2002-03-08 | 2004-02-01 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
WO2003092665A2 (fr) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Systemes oculaires de distribution de medicament et utilisation associee |
BR0317888A (pt) | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos |
US20040208928A1 (en) * | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
US8815284B2 (en) | 2003-06-26 | 2014-08-26 | Psivida Us, Inc. | Bioerodible sustained release drug delivery systems |
DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
MXPA06003599A (es) * | 2003-10-01 | 2006-06-20 | Debio Rech Pharma Sa | Dispositivo y metodo para producir particulas. |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
WO2005110374A1 (fr) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere |
US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
US7572893B2 (en) | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
PT1778723E (pt) | 2004-08-17 | 2013-01-25 | Regeneron Pharma | Formulações de antagonista de il-1 |
AU2005309854A1 (en) | 2004-11-24 | 2006-06-01 | Therakine Ltd. | An implant for intraocular drug delivery |
KR100770362B1 (ko) | 2004-12-30 | 2007-10-26 | (주)두비엘 | 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법 |
EP2586459B1 (fr) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Formulations antagonistes du VEGF |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
WO2007130134A2 (fr) | 2005-12-02 | 2007-11-15 | (Osi) Eyetech, Inc. | Microparticules à libération contrôlée |
KR100722607B1 (ko) | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
HUE053612T2 (hu) | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Intravitreális bevitelre alkalmas VEGF-antagonista készítmények |
DE102006030166A1 (de) * | 2006-06-29 | 2008-01-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tempern |
DE102006030164A1 (de) | 2006-06-29 | 2008-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Pulver |
EP1958622A1 (fr) | 2006-11-07 | 2008-08-20 | Royal College of Surgeons in Ireland | Méthode pour la production des microcapsules |
WO2008109886A1 (fr) | 2007-03-08 | 2008-09-12 | The Regents Of The University Of California | Structures topographiquement modifiées et procédés d'utilisation de celles-ci dans des applications de médecine régénérative |
EP2164425B1 (fr) | 2007-03-16 | 2015-10-28 | The Regents of The University of California | Implants médicaux revêtus d'une surface nanostructurelle et procédés d'utilisation de ceux-ci |
KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
JP2010532749A (ja) * | 2007-06-07 | 2010-10-14 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 質量を削減した長時間作用剤形 |
KR20100103846A (ko) | 2007-12-21 | 2010-09-28 | 메르크 파텐트 게엠베하 | 내부 고체 코어 내에 성장 호르몬을 함유하는 고체 지질 마이크로캡슐 |
CA2711984A1 (fr) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Composition de proteine pulverisee et procedes de fabrication de celle-ci |
CN104887389B (zh) | 2009-01-29 | 2017-06-23 | 弗赛特影像4股份有限公司 | 后段给药 |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
WO2010111132A2 (fr) * | 2009-03-27 | 2010-09-30 | Bend Research, Inc. | Procédé de séchage par pulvérisation |
CN101559041B (zh) | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | 粒径均一的多肽药物缓释微球或微囊制剂及制备方法 |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
US8417452B2 (en) | 2009-08-19 | 2013-04-09 | General Motors Llc | System for providing information to an operator of a vehicle |
EP2482804A1 (fr) * | 2009-10-01 | 2012-08-08 | Evonik Degussa Corporation | Compositions à base de microparticules et méthodes de traitement de la dégénérescence maculaire liée à l'âge |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
DK2600930T3 (da) | 2010-08-05 | 2021-03-01 | Forsight Vision4 Inc | Injektionsapparat til lægemiddelafgivelse |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
SG189220A1 (en) | 2010-10-06 | 2013-05-31 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
SG194155A1 (en) | 2011-04-14 | 2013-11-29 | Univ California | Multilayer thin film drug delivery device and methods of making and using the same |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
SG10202103003RA (en) | 2011-11-18 | 2021-05-28 | Regeneron Pharma | Polymer protein microparticles |
AU2013262611B2 (en) | 2012-05-18 | 2018-03-01 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
BR112014029760A2 (pt) | 2012-05-30 | 2017-06-27 | Univ California | dispositivos de distribuição de agente bioativo e métodos para fazer e usar os mesmos |
US9463177B2 (en) | 2012-09-10 | 2016-10-11 | The Regents Of The University Of California | Compounds and methods for modulating vascular injury |
JP6419775B2 (ja) | 2013-03-19 | 2018-11-07 | バイオテック ツールズ エスエー | アレルゲン調製物 |
AU2015289967A1 (en) | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
IL310557A (en) | 2015-10-16 | 2024-03-01 | Regeneron Pharma | Stable protein compounds |
CN108347935A (zh) | 2015-11-05 | 2018-07-31 | 巴斯夫欧洲公司 | 用于防治植物病原性真菌的取代噁二唑类 |
US20200289514A1 (en) | 2015-11-13 | 2020-09-17 | Novartis Ag | Novel Pyrazolo Pyrimidine Derivatives |
TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
MX2018005383A (es) | 2015-12-07 | 2018-08-16 | Acetate Int Llc | Composiciones formadoras de pelicula de acetato de celulosa. |
CN108368040A (zh) | 2015-12-15 | 2018-08-03 | 默沙东公司 | 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法 |
PL3389636T3 (pl) | 2015-12-16 | 2022-11-28 | Regeneron Pharmaceuticals, Inc. | Kompozycje i metody wytwarzania mikrocząstek białkowych |
-
2012
- 2012-11-18 SG SG10202103003RA patent/SG10202103003RA/en unknown
- 2012-11-18 PL PL19180351T patent/PL3574897T3/pl unknown
- 2012-11-18 CN CN201280056324.6A patent/CN103957898B/zh active Active
- 2012-11-18 FI FIEP12795967.4T patent/FI2790681T4/fi active
- 2012-11-18 IL IL303832A patent/IL303832A/en unknown
- 2012-11-18 PT PT191803519T patent/PT3574897T/pt unknown
- 2012-11-18 CA CA3076725A patent/CA3076725A1/fr active Pending
- 2012-11-18 KR KR1020147014549A patent/KR102133352B1/ko active IP Right Grant
- 2012-11-18 PL PL18173299T patent/PL3384903T3/pl unknown
- 2012-11-18 RU RU2018101248A patent/RU2768492C2/ru active
- 2012-11-18 BR BR112014011915-5A patent/BR112014011915B1/pt active IP Right Grant
- 2012-11-18 CN CN201610035281.3A patent/CN105688188A/zh active Pending
- 2012-11-18 ES ES18173299T patent/ES2810003T3/es active Active
- 2012-11-18 HU HUE18173299A patent/HUE051644T2/hu unknown
- 2012-11-18 DK DK12795967.4T patent/DK2790681T4/da active
- 2012-11-18 SG SG11201402152YA patent/SG11201402152YA/en unknown
- 2012-11-18 EP EP12795967.4A patent/EP2790681B9/fr active Active
- 2012-11-18 RU RU2014124682A patent/RU2642664C2/ru active
- 2012-11-18 PT PT181732991T patent/PT3384903T/pt unknown
- 2012-11-18 MX MX2014005997A patent/MX362286B/es active IP Right Grant
- 2012-11-18 KR KR1020217004470A patent/KR20210021112A/ko not_active IP Right Cessation
- 2012-11-18 KR KR1020207003704A patent/KR102218223B1/ko active IP Right Grant
- 2012-11-18 ES ES12795967T patent/ES2775104T5/es active Active
- 2012-11-18 KR KR1020227014819A patent/KR20220063293A/ko not_active Application Discontinuation
- 2012-11-18 DK DK18173299.1T patent/DK3384903T3/da active
- 2012-11-18 DK DK19180351.9T patent/DK3574897T3/da active
- 2012-11-18 PL PL12795967.4T patent/PL2790681T5/pl unknown
- 2012-11-18 AU AU2012340107A patent/AU2012340107B2/en active Active
- 2012-11-18 HU HUE12795967A patent/HUE048597T2/hu unknown
- 2012-11-18 ES ES19180351T patent/ES2909777T3/es active Active
- 2012-11-18 EP EP18173299.1A patent/EP3384903B1/fr active Active
- 2012-11-18 EP EP22150172.9A patent/EP4026543A1/fr active Pending
- 2012-11-18 JP JP2014542536A patent/JP6267649B2/ja active Active
- 2012-11-18 EP EP19180351.9A patent/EP3574897B1/fr active Active
- 2012-11-18 WO PCT/US2012/065735 patent/WO2013075068A1/fr active Application Filing
- 2012-11-18 CA CA2855749A patent/CA2855749C/fr active Active
- 2012-11-18 IL IL277958A patent/IL277958B2/en unknown
- 2012-11-18 US US13/680,069 patent/US20130129830A1/en not_active Abandoned
-
2014
- 2014-04-29 IL IL232328A patent/IL232328B/en active IP Right Grant
- 2014-05-12 ZA ZA2014/03379A patent/ZA201403379B/en unknown
- 2014-05-16 MX MX2019000382A patent/MX2019000382A/es unknown
-
2017
- 2017-03-06 US US15/450,335 patent/US11291636B2/en active Active
- 2017-08-02 JP JP2017149732A patent/JP6549653B2/ja active Active
-
2018
- 2018-01-05 ZA ZA2018/00078A patent/ZA201800078B/en unknown
- 2018-10-28 IL IL262651A patent/IL262651B/en active IP Right Grant
-
2019
- 2019-04-19 JP JP2019079952A patent/JP6727372B2/ja active Active
-
2020
- 2020-02-05 ZA ZA2020/00742A patent/ZA202000742B/en unknown
- 2020-06-30 JP JP2020112359A patent/JP7217247B2/ja active Active
-
2022
- 2022-02-22 US US17/677,282 patent/US11951216B2/en active Active
-
2023
- 2023-01-23 JP JP2023007775A patent/JP2023052564A/ja active Pending
-
2024
- 2024-03-07 US US18/598,435 patent/US20240207194A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277958A (en) | Micro-particles of polymeric proteins | |
HK1198356A1 (en) | Macromolecules | |
ZA201309001B (en) | Polymer particles | |
EP2754747A4 (fr) | Objet moulé à base de fibres inorganiques | |
GB2501047B (en) | Polymer | |
GB201221246D0 (en) | Polymer blends | |
GB201111183D0 (en) | Peptide | |
GB201115910D0 (en) | Peptides | |
GB2499491B (en) | Compatibilised polymer blends | |
EP2733361A4 (fr) | Turbocompresseur | |
GB201105482D0 (en) | Polymers | |
PL2794110T3 (pl) | Granulator | |
EP2707420A4 (fr) | Matières plastiques et polymères issus de protéines animales | |
EP2728198A4 (fr) | Turbocompresseur | |
GB201107468D0 (en) | Protein expression systems | |
EP2773330A4 (fr) | Procédés d'obtention de microparticules de protéines | |
GB201213672D0 (en) | Protein | |
EP2714717A4 (fr) | Peptides de phoenixin | |
EP2733360A4 (fr) | Turbocompresseur | |
GB2487794B (en) | Microparticles | |
AU2012905215A0 (en) | Microparticles | |
GB201215901D0 (en) | Protein modification | |
GB201103169D0 (en) | Protein expression | |
HUP1100282A2 (en) | Protein factor | |
GB201113089D0 (en) | Protein hydrolysates |